OncologyCE
LECTURECMECPECNE

EGFR T790M-Mutated NSCLC: The Latest on Testing and Treating

Author(s)/Faculty: Eric S. Nadler, MD, MPP; Kartik Konduri, MD
Release Date: 5/11/2018Expiration Date: 5/10/2019
Credit Type: CME / CPE / CNENumber of Credits: 0.5
Content Type: LectureProvider:
Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be about 234,030 new cases of lung cancer and about 154,050 disease-related deaths in the United States in 2018. Approximately 85% of diagnosed lung cancers are non-small cell lung cancer (NSCLC). Mutational evaluation of NSCLC has revolutionized targeted therapeutic options for these patients, and newer, less invasive methods to test for actionable mutations are now available. Tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EFGR) are effectively utilized in many patients with NSCLC; however, resistance to these inhibitors can occur, most frequently through acquisition of the T790M mutation. In this CME activity, experts in the field will review and discuss the importance of mutational testing in NSCLC, the safety and efficacy of current and emerging front-line EGFR inhibitors, and the identification and effective management of patients who acquire the T790M mutation. Expert guidance for the integration of testing, treatment, and management of NSCLC patients with EGFR mutations will be provided through the presentation of clinical case studies.